Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.47 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | VEGFA | P15692 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30915555 | 0.85 | MCOLN3 (0.51) | PGRNR1H3 | |
| SCHEMBL410063 | 0.85 | MCOLN3 (0.51) | PGRNR1H3 | |
| Hydrochloric Acid SCHEMBL29739267 | 0.83 | MCOLN3 (0.50) | PGRNR1H3 | |
| SCHEMBL890823 | 0.82 | BRD4 (0.53) | BRD4EPAS1VEGFA | |
| SCHEMBL7975096 | 0.82 | BRD4 (0.56) | BRD4EPAS1VEGFA | |
| SCHEMBL8379001 | 0.81 | PDE4A (0.54) | PGREPAS1PDE4APDE4BPDE4C | |
| SCHEMBL14018981 | 0.80 | NR1H2 (0.55) | PGRNR1H2NR1H3GCK | |
| SCHEMBL10833690 | 0.79 | HRH3 (0.50) | PGRBRD4EPAS1HAO1CKS1B | |
| SCHEMBL27839327 | 0.79 | PDE4A (0.53) | PGREPAS1PDE4APDE4BPDE4C | |
| SCHEMBL10923033 | 0.77 | PDE4A (0.55) | PGREPAS1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273816-A1 | Quinazoline Compounds | WYETH LLC | 2010-10-28 | — | — | US | disclosed |
| EP-2142517-A2 | QUINAZOLINE COMPOUNDS | Wyeth (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2009020683-A2 | QUINAZOLINE COMPOUNDS | WYETH (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273816-A1 | Quinazoline Compounds | NR1H3, NR1H2, NR1I3 | PGR 497/4885BRD4 375/4885EPAS1 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.